2026-05-07

USDC/USDT has $188.2M volume but only $884K liquidity — thin market, slippage risk

BTC ETF inflow of $272M — institutional buying

USDUC/SOL crashed -52.0% in 24h on pumpswap DEX

ETH ETF inflow of $116M — institutional buying

USDC/USDT has $199.3M volume but only $884K liquidity — thin market, slippage risk

BTC ETF inflow of $272M — institutional buying

USDUC/SOL crashed -22.1% in 24h on pumpswap DEX

ETH ETF inflow of $116M — institutional buying

USDC/USDT has $169.6M volume but only $884K liquidity — thin market, slippage risk

BTC ETF inflow of $251M — institutional buying

USDC/USDT has $182.2M volume but only $884K liquidity — thin market, slippage risk

BTC ETF inflow of $251M — institutional buying

ETH DEX volume/liquidity ratio elevated (0.57x) — strong on-chain trading activity

SOL DEX volume/liquidity ratio elevated (0.68x) — strong on-chain trading activity

ETH DEX volume/liquidity ratio elevated (0.54x) — strong on-chain trading activity

SOL DEX volume/liquidity ratio elevated (0.78x) — strong on-chain trading activity

FDA approves drug (Pfizer) — new revenue stream

FDA approves drug (Pfizer) — new revenue stream

FDA approves drug (Pfizer) — new revenue stream

FDA approves CLINDAMYCIN PHOSPHATE (Pfizer) — new revenue stream

FDA approves drug (Pfizer) — new revenue stream

FDA approves PROCARDIA XL (Pfizer) — new revenue stream

FDA approves CLEOCIN PEDIATRIC (Pfizer) — new revenue stream

FDA approves drug (Pfizer) — new revenue stream

FDA approves PROCARDIA XL (Pfizer) — new revenue stream

FDA approves CLINDAMYCIN PHOSPHATE (Pfizer) — new revenue stream

FDA approves CLEOCIN HYDROCHLORIDE (Pfizer) — new revenue stream

FDA approves CLINDAMYCIN PHOSPHATE (Pfizer) — new revenue stream

FDA approves drug (Pfizer) — new revenue stream

FDA approves drug (Pfizer) — new revenue stream

FDA approves AZULFIDINE EN-TABS (Pfizer) — new revenue stream

FDA approves drug (Pfizer) — new revenue stream

FDA approves drug (Pfizer) — new revenue stream

FDA approves PROCARDIA XL (Pfizer) — new revenue stream

FDA approves drug (Pfizer) — new revenue stream

FDA approves drug (Pfizer) — new revenue stream

FDA approves drug (Pfizer) — new revenue stream

FDA approves drug (Pfizer) — new revenue stream

FDA approves drug (Pfizer) — new revenue stream

FDA approves drug (Pfizer) — new revenue stream

FDA approves CLEOCIN PEDIATRIC (Pfizer) — new revenue stream

FDA approves CLEOCIN PEDIATRIC (Pfizer) — new revenue stream

FDA approves drug (Pfizer) — new revenue stream

FDA approves AZULFIDINE EN-TABS (Pfizer) — new revenue stream

FDA approves drug (Pfizer) — new revenue stream

FDA approves CLEOCIN HYDROCHLORIDE (Pfizer) — new revenue stream

FDA approves CLEOCIN HYDROCHLORIDE (Pfizer) — new revenue stream

FDA approves AZULFIDINE EN-TABS (Pfizer) — new revenue stream

FDA approves drug (Merck) — new revenue stream

FDA approves drug (Merck) — new revenue stream

FDA approves drug (Merck) — new revenue stream

FDA approves drug (Merck) — new revenue stream

FDA approves drug (Merck) — new revenue stream

FDA approves drug (Merck) — new revenue stream

FDA approves drug (Merck) — new revenue stream

FDA approves drug (Merck) — new revenue stream

FDA approves drug (Merck) — new revenue stream

FDA approves drug (Merck) — new revenue stream

FDA approves drug (Merck) — new revenue stream

FDA approves drug (Merck) — new revenue stream

FDA approves drug (Merck) — new revenue stream

FDA approves drug (Merck) — new revenue stream

FDA approves drug (Merck) — new revenue stream

FDA approves drug (Merck) — new revenue stream

FDA approves drug (Merck) — new revenue stream

FDA approves drug (Merck) — new revenue stream

FDA approves drug (Lilly) — new revenue stream

FDA approves drug (Lilly) — new revenue stream

FDA approves drug (Lilly) — new revenue stream

FDA approves drug (Lilly) — new revenue stream

FDA approves drug (Lilly) — new revenue stream

FDA approves drug (Lilly) — new revenue stream

FDA approves drug (Lilly) — new revenue stream

FDA approves drug (Lilly) — new revenue stream

FDA approves drug (Lilly) — new revenue stream

FDA approves drug (Lilly) — new revenue stream

FDA approves drug (Lilly) — new revenue stream

FDA approves drug (Lilly) — new revenue stream

FDA approves drug (Lilly) — new revenue stream

FDA approves drug (Lilly) — new revenue stream

FDA approves drug (Lilly) — new revenue stream

FDA approves drug (Lilly) — new revenue stream

FDA approves drug (Lilly) — new revenue stream

FDA approves drug (Lilly) — new revenue stream

FDA approves drug (Lilly) — new revenue stream

FDA approves drug (Lilly) — new revenue stream

FDA approves drug (Lilly) — new revenue stream

FDA approves drug (Lilly) — new revenue stream

FDA approves drug (Lilly) — new revenue stream

FDA approves drug (Lilly) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves VUITY (AbbVie) — new revenue stream

FDA approves VUITY (AbbVie) — new revenue stream

FDA approves VUITY (AbbVie) — new revenue stream

FDA approves ZEMPLAR (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves ZEMPLAR (AbbVie) — new revenue stream

FDA approves ZEMPLAR (AbbVie) — new revenue stream

FDA approves UBRELVY (AbbVie) — new revenue stream

FDA approves UBRELVY (AbbVie) — new revenue stream

FDA approves UBRELVY (AbbVie) — new revenue stream

FDA approves MAVYRET (AbbVie) — new revenue stream

FDA approves FML FORTE (AbbVie) — new revenue stream

FDA approves MAVYRET (AbbVie) — new revenue stream

FDA approves MAVYRET (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves OXYTROL FOR WOMEN (AbbVie) — new revenue stream

FDA approves OXYTROL FOR WOMEN (AbbVie) — new revenue stream

FDA approves OXYTROL FOR WOMEN (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves ESTRADIOL (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves ESTRADIOL (AbbVie) — new revenue stream

FDA approves FML FORTE (AbbVie) — new revenue stream

FDA approves FML FORTE (AbbVie) — new revenue stream

FDA approves ESTRADIOL (AbbVie) — new revenue stream

FDA approves DEPAKOTE ER (AbbVie) — new revenue stream

FDA approves DEPAKOTE ER (AbbVie) — new revenue stream

FDA approves DEPAKOTE ER (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves CELEXA (AbbVie) — new revenue stream

FDA approves CELEXA (AbbVie) — new revenue stream

FDA approves CELEXA (AbbVie) — new revenue stream

FDA approves RINVOQ (AbbVie) — new revenue stream

FDA approves RINVOQ (AbbVie) — new revenue stream

FDA approves RINVOQ (AbbVie) — new revenue stream

FDA approves drug (AbbVie) — new revenue stream

FDA approves drug (Abbott) — new revenue stream

FDA approves drug (Abbott) — new revenue stream

FDA approves drug (Abbott) — new revenue stream

FDA approves drug (Abbott) — new revenue stream

FDA approves drug (Abbott) — new revenue stream

FDA approves drug (Abbott) — new revenue stream

FDA approves drug (Abbott) — new revenue stream

FDA approves drug (Abbott) — new revenue stream

Equifax search volume spiked +69 pts — unusual interest

American Water Works search volume spiked +100 pts — unusual interest

General Motors search volume spiked +56 pts — unusual interest

GE Aerospace search volume spiked +53 pts — unusual interest

Evergy search volume spiked +49 pts — unusual interest

Alliant Energy search volume spiked +62 pts — unusual interest

Equifax search volume spiked +69 pts — unusual interest

American Water Works search volume spiked +100 pts — unusual interest

GE Aerospace search volume spiked +53 pts — unusual interest

Evergy search volume spiked +49 pts — unusual interest

Alliant Energy search volume spiked +62 pts — unusual interest

American Water Works search volume spiked +100 pts — unusual interest

AAPL RSI 71.1 — overbought (crossed above 70)

Equifax search volume spiked +69 pts — unusual interest

General Motors search volume spiked +44 pts — unusual interest

GE Aerospace search volume spiked +53 pts — unusual interest

Missed consensus by 20.2% — EPS $0.58 vs $0.7268 estimate

Missed consensus by 18.5% — EPS $0.33 vs $0.4048 estimate

Missed consensus by 34.8% — EPS $0.34 vs $0.5211 estimate

Beat consensus by 15.0% — EPS $3.06 vs $2.6612 estimate

Beat consensus by 9.5% — EPS $1.9 vs $1.7355 estimate

Beat consensus by 9.4% — EPS $3.11 vs $2.8425 estimate

Beat consensus by 15.7% — EPS $4.1 vs $3.544 estimate

Beat consensus by 8.9% — EPS $2.61 vs $2.3972 estimate

Beat consensus by 7.8% — EPS $2.84 vs $2.6356 estimate

Beat consensus by 5.5% — EPS $1.82 vs $1.7248 estimate

Missed consensus by 6.2% — EPS $2.01 vs $2.142 estimate

Beat consensus by 8.2% — EPS $1.28 vs $1.1828 estimate

Beat consensus by 20.5% — EPS $1.11 vs $0.9212 estimate

Beat consensus by 38.6% — EPS $0.7 vs $0.505 estimate

Beat consensus by 5.2% — EPS $4.73 vs $4.497 estimate

Beat consensus by 9.6% — EPS $1.86 vs $1.6968 estimate

Missed consensus by 78.7% — EPS $0.43 vs $2.016 estimate

Beat consensus by 15.1% — EPS $1.69 vs $1.4685 estimate

Beat consensus by 7.3% — EPS $1.48 vs $1.3788 estimate

Beat consensus by 5.9% — EPS $1.32 vs $1.2464 estimate

Missed consensus by 6.9% — EPS $0.55 vs $0.5908 estimate

Beat consensus by 10.5% — EPS $1.03 vs $0.9322 estimate

Beat consensus by 6.3% — EPS $3.67 vs $3.4541 estimate

Missed consensus by 10.9% — EPS $3.39 vs $3.8047 estimate

Beat consensus by 57.9% — EPS $23.41 vs $14.8274 estimate

Beat consensus by 76.3% — EPS $6.2 vs $3.5172 estimate

Beat consensus by 27.8% — EPS $1.22 vs $0.9543 estimate

Beat consensus by 597.1% — EPS $0.29 vs $0.0416 estimate

Missed consensus by 5.1% — EPS $0.58 vs $0.6111 estimate

Beat consensus by 32.3% — EPS $0.84 vs $0.6349 estimate

Missed consensus by 14.9% — EPS $0.35 vs $0.4112 estimate

Beat consensus by 38.7% — EPS $0.69 vs $0.4976 estimate

Missed consensus by 8.4% — EPS $0.41 vs $0.4476 estimate

Missed consensus by 10.9% — EPS $0.22 vs $0.2469 estimate

Missed consensus by 7.8% — EPS $0.61 vs $0.6616 estimate

Missed consensus by 6.3% — EPS $0.56 vs $0.5978 estimate

Missed consensus by 9.5% — EPS $0.52 vs $0.5743 estimate

Oil -6.16% — significant selloff

Oil +2.78% — significant rally

Oil -3.16% — significant selloff

Gold +1.56% — significant rally

Oil -2.04% — significant selloff

baltic_dry shipping +5.6% — potential inflation signal

baltic_dry shipping +5.6% — potential inflation signal

baltic_dry shipping +5.6% — potential inflation signal